Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification

Abstract

Cervical carcinoma (CC) has been associated with high morbidity, poor prognosis, and high intratumor heterogeneity. Necroptosis is the significant cellular signal pathway in tumors which may overcome tumor cells’ apoptosis resistance. To investigate the relationship between CC and necroptosis, we established a prognostic model based on necroptosis-related genes for predicting the overall survival (OS) of CC patients. The gene expression data and clinical information of cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) patients were obtained from The Cancer Genome Atlas (TCGA). We identified 43 differentially expressed necroptosis-related genes (NRGs) in CESC by examining differential gene expression between CESC tumors and normal tissues, and 159 NRGs from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Gene ontology (GO) and KEGG enrichment analysis illustrated that the genes identified were mainly related to cell necrosis, extrinsic apoptosis, Influenza A, I − kappaB kinase/NF − kappaB, NOD − like receptor, and other signaling pathways. Subsequently, least absolute shrinkage and selection operator (LASSO) regression and univariate and multivariate Cox regression analyses were used to screen for NRGs that were correlated with patient prognosis. A prognostic signature that includes CAMK2A, CYBB, IL1A, IL1B, SLC25A5, and TICAM2 was established. Based on the prognostic model, patients were stratified into either the high-risk or low-risk subgroups with distinct survival. Receiver operating characteristic (ROC) curve analysis was used to identify the predictive accuracy of the model. In relation to different clinical variables, stratification analyses were performed to demonstrate the associations between the expression levels of the six identified NRGs and the clinical variables in CESC. Immunohistochemical (IHC) validation experiments explored abnormal expressions of these six NRGs in CESC. We also explored the relationship between risk score of this necroptosis signature and expression levels of some driver genes in TCGA CESC database and Gene Expression Omnibus (GEO) datasets. Significant relationships between the six prognostic NRGs and immune-cell infiltration, chemokines, tumor mutation burden (TMB), microsatellite instability (MSI), and immune checkpoints in CESC were discovered. In conclusion, we successfully constructed and validated a novel NRG signature for predicting the prognosis of CC patients and might also play a crucial role in the progression and immune microenvironment in CC.

RIPK1 and RIPK3 are positive prognosticators for cervical cancer patients and C2 ceramide can inhibit tumor cell proliferation in vitro

“…The progression-free survival of patients in the high-RIPK1 expression group ( n = 131) was insignificantly worse compared to patients in the low-expression group ( n = 43). This correlates with the results of our cohort even though we did not use the C-index, which is a useful tool for analysing different datasets ( 42 , 43 ).…”

“…Sources of the KM plotter database include GEO, EGA and TCGA ( 41 ). Specifically, the use of GEO and TCGA datasets have already been published on cervical cancer ( 42 , 43 ). We divided patients into high and low groups of expression of RIPK1 using auto select best cut-off.…”

Construction and validation of a necroptosis-related prognostic signature in acute myeloid leukemia

“…[28] Sun et al developed a prognostic model based on 6 NRGs, including CYBB, related to necroptosis to predict the OS in patients with cervical cancer. [29] Liu et al discovered that HMGB1, an NRG, plays a dual role in AML cells by not only activating the NF-κB signaling pathway but also serve as a regulator to control immune system and initiate an inflammatory response, ultimately preventing necroptosis of AML cells. [30] Thus, these investigations have highlighted the significance of enhancing the effectiveness of chemotherapy and immunotherapy in AML through the advancement of gene therapy techniques that stimulate necroptosis.…”

Identification and Experimental Validation of Genes Associated with Programmed Cell Death in Dendritic Cells of the Thyroid Tissue in Hashimoto's Thyroiditis

“…2023). CYBB was identi ed as an upregulated necroptosis signature in colon, cervical, and pancreatic adenocarcinomas(Wang et al 2022;Wu et al 2022;Sun et al 2022). CYBB crucially suppressed ferroptosis through the CYBB/Nrf2/SOD2 axis in mesenchymal glioblastoma multiforme(Su et al 2023).…”